ArticleClinical lipidology2012
Hepatobiliary transport in health and disease.
Article in Clinical lipidology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Gene expression and DNA methylation changes in response to hypoxia in toxicant-adapted Atlantic killifish (Fundulus heteroclitus).Biology open · 2025Article
- Ursodeoxycholic acid treatment of LPAC presenting as post cholecystectomy pain: rationale and design of a randomised trial.Translational gastroenterology and hepatology · 2025Article
- [Child with sitosterolemia initially presenting with hemolytic anemia and thrombocytopenia: a case repore and literrature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Article
- The interplay between bile acids and mucosal adaptive immunity.PLoS pathogens · 2023Article
- Insight into the mechanism of gallstone disease by proteomic and metaproteomic characterization of human bile.Frontiers in microbiology · 2023Article
- Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products.Frontiers in immunology · 2023Review
- Defective humoral immunity disrupts bile acid homeostasis which promotes inflammatory disease of the small bowel.Nature communications · 2022Article
- GPBAR1 is associated with asynchronous bone metastasis and poor prognosis of hepatocellular carcinoma.Frontiers in oncology · 2022Article
- Effect and related mechanism of Yinchenhao decoction on mice with lithogenic diet-induced cholelithiasis.Experimental and therapeutic medicine · 2021Article
- Severe Hepatotoxicity of Mithramycin Therapy Caused by Altered Expression of Hepatocellular Bile Transporters.Molecular pharmacology · 2019Article
- Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases.Journal of biomedical science · 2018Review
- [Clinical and genetic analysis of an infant with progressive familial intrahepatic cholestasis type II].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2018Article
- Article
- Predicting Drug-Induced Cholestasis with the Help of Hepatic Transporters-An in Silico Modeling Approach.Journal of chemical information and modeling · 2017Article
- [Not Available].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bile salts, cholesterol and phosphatidylcholine are secreted across the canalicular membrane of hepatocytes into bile by ATP-binding cassette (ABC) transporters. Secretion of bile salts by ABCB11 is essential for bile flow and for absorption of lipids and fat-soluble vitamins. ABCG5 and ABCG8 eliminate excess cholesterol and sterols from the body by secreting them into bile. There are two mechanisms to protect the canalicular membrane from solubilization by bile salts; ABCB4 secretes phosphatidylcholine into bile to form mixed micelles with bile salts, and ATP8B1 maintains the canalicular membrane in a liquid-ordered state. Three different forms of progressive familial intrahepatic cholestasis (PFIC) disorders, PFIC1, PFIC2 and PFIC3, are caused by mutations in ATP8B1, ABCB11 and ABCB4, respectively. Sitosterolemia is caused by mutations in ABCG5 and ABCG8. This article reviews the physiological roles of these canalicular transporters, and the pathophysiological processes and clinical features associated with their mutations.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.